# Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis

> **NCT02473341** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Dayanand Medical College and Hospital** · enrollment: 174 (actual)

## Conditions studied

- Alcoholic Hepatitis

## Interventions

- **DRUG:** Bovine Colostrum
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02473341
- **Lead sponsor:** Dayanand Medical College and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-14
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473341, "Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02473341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*